The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trial Required)
The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to continue support for the Experimental Therapeutics Clinical Trials Network (ETCTN) for the efficient and comprehensive conduct of early phase clinical trials of NCI Investigational New Drug (IND) agents. The ETCTN is designed to assure the availability of investigators and programs with expertise in early drug development and translational research for this purpose. This FOA solicits UM1 cooperative agreement applications from appropriate multidisciplinary groups that can assemble an appropriate infrastructure and conduct phase 0, phase 1, phase 2, pilot and other experimental therapeutics clinical trials involving agents for which the NCI’s Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP) received IND status. The FOA is open to any qualified applicant regardless of whether they have been previously associated with the ETCTN.
Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.
- Duke Internal: Duke Cancer Institute will apply for a renewal this year.
- Letter of Intent Due Date(s): 30 days prior to the application due date
- Application Due Date(s): May 22, 2019
RFA-CA-19-007 Expiration Date May 23, 2019
Individual(s) designated as Program Director(s)/Principal Investigator(s) (PDs/PIs) on the applications for ETCTN awards are expected to be nationally- and internationally-recognized leaders in cancer-related clinical trials of novel therapeutic agents, translational research, and related clinical areas relevant to such studies. These individuals should also be recognized leaders in the relevant areas of science and have documented administrative leadership experience.
In addition, an individual designated as a contact PD/PI must have primary affiliation with the application submitting institution (i.e., the LAO). If additional PDs/PIs are designated, they may be affiliated either with the LAO or participating AO.
If the ETCTN contact PD/PI is not a practicing physician, a physician(s) must be designated to be responsible for overseeing the clinical trial(s) and patient management. This physician must have primary affiliation with the submitting institution (i.e., the LAO).
Application budget requests are limited to $1,250,000 (direct costs) per year.
Project period of 6 years should be requested